---
aliases:
  - Thuốc vận mạch
---
# Vận mạch và tăng co bóp trong sốc  
  
![Vận mạch trong sốc-20240808231725172.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240808231725172.webp)  
  
[HDSD-vận-mạch-trong-sốc-BS-Pha-dịch.pdf](%3Cfile:///G:My%20DriveSocHDSD-v%E1%BA%ADn-m%E1%BA%A1ch-trong-s%E1%BB%91c-BS-Pha-d%E1%BB%8Bch.pdf%3E.md)  
  
![HDSD vận mạch và tăng co bóp trong sốc-20240618180723627.webp](./200%20FILES/201%20Image/HDSD%20v%E1%BA%ADn%20m%E1%BA%A1ch%20v%C3%A0%20t%C4%83ng%20co%20b%C3%B3p%20trong%20s%E1%BB%91c-20240618180723627.webp)  
[Bài 13. Các thuốc vân mạnh trong hồi sức - BS. Nguyễn Dương Mỹ Duyên (youtube.com)](youtube.com).md)  
  
## Tổng quan về thuốc vận mạch  
- Thuốc vận mạch (vaspressor) được chỉ định ở những BN vẫn còn hạ HA mặc dù đã được bù dịch đầy đủ  
- Trong hội chứng giảm cung lượng tim, cần phải chỉ định các thuốc tăng co bóp (inotrope)  
- Thuốc vận mạch (vasopressor và inotrope) tác động kích thích và ức chế trên tim và cơ trơn mạch máu cũng như có tác động quan trọng lên chuyển hoá, hệ thần kinh TW và hệ TK tự động tiên sysnapse  
- Mục đích sử dụng là làm tăng cung lượng tim hoặc trương lực mạch máu  
  
![Vận mạch trong sốc-20240618213023864.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213023864.webp)  
  
![Vận mạch trong sốc-20240618213051716.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213051716.webp)  
  
![HDSD vận mạch và tăng co bóp trong sốc-20240618212336183.webp](./200%20FILES/201%20Image/HDSD%20v%E1%BA%ADn%20m%E1%BA%A1ch%20v%C3%A0%20t%C4%83ng%20co%20b%C3%B3p%20trong%20s%E1%BB%91c-20240618212336183.webp)  
  
![HDSD vận mạch và tăng co bóp trong sốc-20240618212655093.webp](./200%20FILES/201%20Image/HDSD%20v%E1%BA%ADn%20m%E1%BA%A1ch%20v%C3%A0%20t%C4%83ng%20co%20b%C3%B3p%20trong%20s%E1%BB%91c-20240618212655093.webp)  
![Vận mạch trong sốc-20240618213117990.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213117990.webp)  
![Vận mạch trong sốc-20240618213912691.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213912691.webp)  
![Vận mạch trong sốc-20240618213944036.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213944036.webp)  
![Vận mạch trong sốc-20240618213949254.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213949254.webp)  
![Vận mạch trong sốc-20240618214000944.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618214000944.webp)  
  
## A global perspective on vasoactive agents in shock  
  
![Vận mạch trong sốc-20240618213407038.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213407038.webp)  
Fig. 1 Impact of norepinephrine and dobutamine on cardiac output and its determinants, regional and microvascular perfusions. The effects of norepinephrine and dobutamine are denoted with colored arrows: blue arrows denote an increase in the corresponding hemodynamic variable, red arrows denote a decrease in the corresponding hemodynamic variable, bicolor red/blue arrows denote variable effects (can be either positive or negative, depending on time, patient condition or blood pressure level). Plain arrows denote an effect observed in the majority of the patients, dotted arrow represent an effect observed in some but not all patients (but without detrimental effect). The thickness of the arrow represents the magnitude of the effect. An evanescent arrow represents an effect that decreases over time  
  
![Vận mạch trong sốc-20240618213508789.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213508789.webp)  
  
## Vasopressor therapy in critically ill patients with shock  
![Vận mạch trong sốc-20240618213716614.webp](./200%20FILES/201%20Image/V%E1%BA%ADn%20m%E1%BA%A1ch%20trong%20s%E1%BB%91c-20240618213716614.webp)  
  
Fig. 3 Algorithm for vasopressor management. In patients with ==vasodilatory shock==, the first priority is Airway, Breathing, and Circulation (ABCs) resuscitation, while in parallel doing laboratory evaluation (arterial blood gases, lactate, hematology, renal and hepatic function) and evaluating the cause of vasodilatory shock. Initial fluids (30 ml/kg initially and more as needed) should be crystalloid. In patients not responding to adequate fluid resuscitation, norepinephrine is started. In patients not responding to norepinephrine, vasopressin (terlipressin) or epinephrine is added. In patients who are profoundly hypotensive, phenylephrine or angiotensin II may be considered. Evaluation of the cause of shock is done in parallel with resus- citation; fever and leukocytosis suggest septic shock. Septic shock requires search for source of sepsis and drainage of abscesses and empyema. Sepsis mimics include post- acute myocardial infarction (AMI), post-cardiovascular surgery and other causes (pancreatitis, aspiration, Acute Respira- tory Distress Syndrome (ARDS), post-abdominal surgery, trauma, and drugs (anesthetics and drug allergy/anaphylaxis).  
1In patients not responsive to norepinephrine, vasopressin, epinephrine or angiotensin II, cardiovascular evaluation is necessary.  
2Cardiovascular evaluation should occur such as limited bedside echocardiograph, non-invasive cardiac output, central venous pressure (CVP) or pulmonary capillary wedge pressure (via pulmonary artery catheter). If there is decreased ventricular function (decreased ejection fraction), then dobutamine should be added.  
3Not responsive to norepinephrine or other vasopressors is not well-defined but generally means not responsive to a high dose.  
4Vasopressin can be substituted with terlipressin but the randomized controlled trials of terlipressin are much smaller than with vasopressin. Sele- pressin (a highly specific AVPR1a agonist) is in development  
  
  
  
  
  
  
[Thuốc vận mạch và tăng sức bóp cơ tim (Vasopressor & Inotrope) - Bs Tín 06-2024](./Thu%E1%BB%91c%20v%E1%BA%ADn%20m%E1%BA%A1ch%20v%C3%A0%20t%C4%83ng%20s%E1%BB%A9c%20b%C3%B3p%20c%C6%A1%20tim%20(Vasopressor%20&%20Inotrope)%20-%20Bs%20T%C3%ADn%2006-2024.md)  
  
- [b](youtube.com).md)  
  
  
